Arca
Skip to content
Tools
Tools

Anthrax

Drug research and approvals for anthrax: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 3 studies of anthrax are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 5 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 3
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 5
  • EU medicines: 0

Recruiting now

Newest start dates first, of 3 recruiting on ClinicalTrials.gov ↗

Drug pipeline

4 approved, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Obiltoxaximab, Doxycycline anhydrous, Raxibacumab, Bacillus anthracis protective antigen, adsorbed

Ciprofloxacin
Phase 2 Bacterial DNA gyrase inhibitor
Aluminum hydroxide
Phase 2 Antacid
Anthrax vaccine absorbed
Phase 2 Biological vaccine - induces immune response
MDX-1303
Phase 1 Protective antigen inhibitor
Human immunoglobulin g
Phase 1 Replacement therapy, immunomodulatory effects
AVP-21D9
Phase 1 Protective antigen inhibitor

How its trials ended

52 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 12 whose ending is known, 58% met their primary endpoint, 8% missed it and 33% stopped early.

  • Completed, result not reported3465%
  • Met its primary endpoint713%
  • Ongoing612%
  • Stopped: sponsor or business decision24%
  • Stopped: other or unclear24%
  • Missed its primary endpoint12%

FDA orphan designations

Approved first, then open designations, newest first
Jul 20, 2023CyfendusPost-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age…Emergent Product Development Gaithersburg, Inc.Approved
Mar 18, 2016AnthimTreatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial…Elusys Therapeutics, Inc.Approved
Nov 23, 2015BioThraxFor post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction…Emergent BioDefense Operations Lansing LLCApproved
Mar 24, 2015Anthrax immune globulin (human)Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugsCangene Corp. - Emergent BiosolutionsApproved
Dec 14, 2012ABthraxTMTreatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,Human Genome Sciences, Inc.Approved
Apr 26, 2026Omadacycline p-toluenesulfonatePost-exposure prophylaxis (PEP) of anthrax infectionParatek Pharmaceuticals, Inc.Designated
Apr 26, 2026Omadacycline p-toluenesulfonateTreatment of anthraxParatek Pharmaceuticals, Inc.Designated
Jun 21, 2018L-alanoyl-D-glutamate endopeptidase from Bacillus-infected…Treatment of inhalational anthraxiNtRON Biotechnology, Inc.Designated
Feb 28, 2007CethromycinProphylactic treatment of patients exposed to inhalation anthrax.Advanced LIfe Sciences, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.